PetMed Express, Inc. Logo

PetMed Express, Inc.

PETS

(1.2)
Stock Price

4,97 USD

-2.91% ROA

-1% ROE

-24.61x PER

Market Cap.

83.020.821,00 USD

1.41% DER

0% Yield

-0.37% NPM

PetMed Express, Inc. Stock Analysis

PetMed Express, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PetMed Express, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (2%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Dividend

Investors can trust the company's impressive dividend track record, consistently distributing dividends over the past five years, showcasing a strong commitment to rewarding shareholders.

3 PBV

The stock's PBV ratio (1.37x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

4 ROE

Negative ROE (-4.97%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-5.08%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-44), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

PetMed Express, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PetMed Express, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

PetMed Express, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PetMed Express, Inc. Revenue
Year Revenue Growth
2000 14.677.146
2001 10.006.285 -46.68%
2002 32.025.931 68.76%
2003 54.974.916 41.74%
2004 93.994.233 41.51%
2005 108.357.747 13.26%
2006 137.583.155 21.24%
2007 162.246.407 15.2%
2008 188.336.469 13.85%
2009 219.412.247 14.16%
2010 238.265.933 7.91%
2011 231.642.000 -2.86%
2012 238.250.000 2.77%
2013 227.829.000 -4.57%
2014 233.391.000 2.38%
2015 229.395.000 -1.74%
2016 234.684.000 2.25%
2017 249.176.000 5.82%
2018 273.800.000 8.99%
2019 283.419.000 3.39%
2020 284.125.000 0.25%
2021 309.215.000 8.11%
2022 273.417.000 -13.09%
2023 256.858.000 -6.45%
2024 283.996.000 9.56%
2024 281.064.000 -1.04%
2025 271.808.000 -3.41%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PetMed Express, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%
2024 0 0%
2025 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PetMed Express, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 7.370.916
2001 4.506.509 -63.56%
2002 6.094.493 26.06%
2003 7.956.786 23.41%
2004 10.754.427 26.01%
2005 11.396.320 5.63%
2006 14.078.343 19.05%
2007 17.292.675 18.59%
2008 20.367.392 15.1%
2009 21.604.654 5.73%
2010 22.341.123 3.3%
2011 22.200.000 -0.64%
2012 22.363.000 0.73%
2013 21.592.000 -3.57%
2014 21.352.000 -1.12%
2015 21.101.000 -1.19%
2016 21.301.000 0.94%
2017 22.799.000 6.57%
2018 24.290.000 6.14%
2019 24.767.000 1.93%
2020 25.264.000 1.97%
2021 28.293.000 10.71%
2022 30.829.000 8.23%
2023 49.474.000 37.69%
2024 53.112.000 6.85%
2024 55.246.000 3.86%
2025 19.496.000 -183.37%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PetMed Express, Inc. EBITDA
Year EBITDA Growth
2000 -1.741.181
2001 -2.256.129 22.82%
2002 1.211.977 286.15%
2003 3.829.596 68.35%
2004 9.754.848 60.74%
2005 13.071.733 25.37%
2006 18.475.912 29.25%
2007 21.595.891 14.45%
2008 27.941.722 22.71%
2009 34.615.943 19.28%
2010 41.859.010 17.3%
2011 34.527.000 -21.24%
2012 27.372.000 -26.14%
2013 28.096.000 2.58%
2014 29.085.000 3.4%
2015 31.701.000 8.25%
2016 33.232.000 4.61%
2017 38.852.000 14.47%
2018 54.262.000 28.4%
2019 48.399.000 -12.11%
2020 33.234.000 -45.63%
2021 40.014.000 16.94%
2022 28.448.000 -40.66%
2023 2.116.000 -1244.42%
2024 5.088.000 58.41%
2024 94.000 -5312.77%
2025 24.428.000 99.62%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PetMed Express, Inc. Gross Profit
Year Gross Profit Growth
2000 5.615.384
2001 3.638.681 -54.32%
2002 13.131.438 72.29%
2003 23.457.277 44.02%
2004 38.169.827 38.54%
2005 43.657.745 12.57%
2006 54.338.789 19.66%
2007 64.566.169 15.84%
2008 74.214.036 13%
2009 85.327.567 13.02%
2010 91.860.639 7.11%
2011 83.956.000 -9.42%
2012 80.165.000 -4.73%
2013 77.121.000 -3.95%
2014 77.617.000 0.64%
2015 76.270.000 -1.77%
2016 76.296.000 0.03%
2017 79.314.000 3.81%
2018 97.807.000 18.91%
2019 95.314.000 -2.62%
2020 81.246.000 -17.32%
2021 89.948.000 9.67%
2022 78.076.000 -15.21%
2023 71.014.000 -9.94%
2024 80.248.000 11.51%
2024 71.592.000 -12.09%
2025 65.000.000 -10.14%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PetMed Express, Inc. Net Profit
Year Net Profit Growth
2000 -1.794.237
2001 -2.826.707 36.53%
2002 825.413 442.46%
2003 3.257.565 74.66%
2004 5.813.604 43.97%
2005 8.010.370 27.42%
2006 12.063.514 33.6%
2007 14.443.502 16.48%
2008 20.022.231 27.86%
2009 22.976.411 12.86%
2010 26.002.467 11.64%
2011 20.871.000 -24.59%
2012 16.659.000 -25.28%
2013 17.165.000 2.95%
2014 17.972.000 4.49%
2015 17.453.000 -2.97%
2016 20.567.000 15.14%
2017 23.819.000 13.65%
2018 37.283.000 36.11%
2019 37.740.000 1.21%
2020 25.851.000 -45.99%
2021 23.919.000 -8.08%
2022 18.716.000 -27.8%
2023 233.000 -7932.62%
2024 -280.000 183.21%
2024 -7.464.000 96.25%
2025 15.016.000 149.71%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PetMed Express, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 1 0%
2007 1 0%
2008 1 0%
2009 1 0%
2010 1 100%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 100%
2017 1 0%
2018 2 0%
2019 2 0%
2020 1 0%
2021 2 0%
2022 1 0%
2023 0 0%
2024 0 0%
2024 0 0%
2025 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PetMed Express, Inc. Free Cashflow
Year Free Cashflow Growth
2000 -869.337
2001 -1.288.471 32.53%
2002 -79.621 -1518.26%
2003 225.705 135.28%
2004 363.855 37.97%
2005 8.177.042 95.55%
2006 9.519.314 14.1%
2007 15.539.361 38.74%
2008 18.877.788 17.68%
2009 11.273.069 -67.46%
2010 26.638.716 57.68%
2011 29.429.000 9.48%
2012 19.686.000 -49.49%
2013 12.664.000 -55.45%
2014 13.461.000 5.92%
2015 31.125.000 56.75%
2016 923.000 -3272.16%
2017 36.600.000 97.48%
2018 36.676.000 0.21%
2019 44.518.000 17.62%
2020 36.533.000 -21.86%
2021 37.643.000 2.95%
2022 16.746.000 -124.79%
2023 22.543.000 25.72%
2024 -194.000 11720.1%
2024 -1.761.000 88.98%
2025 -9.200.000 80.86%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PetMed Express, Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 -317.241
2001 -1.046.583 69.69%
2002 476.024 319.86%
2003 970.301 50.94%
2004 1.105.595 12.24%
2005 8.348.799 86.76%
2006 10.277.490 18.77%
2007 16.564.440 37.95%
2008 19.380.494 14.53%
2009 14.965.684 -29.5%
2010 27.685.565 45.94%
2011 30.106.000 8.04%
2012 20.391.000 -47.64%
2013 13.290.000 -53.43%
2014 13.506.000 1.6%
2015 32.043.000 57.85%
2016 21.053.000 -52.2%
2017 47.204.000 55.4%
2018 37.379.000 -26.28%
2019 45.138.000 17.19%
2020 38.844.000 -16.2%
2021 40.075.000 3.07%
2022 18.498.000 -116.65%
2023 27.803.000 33.47%
2024 4.317.000 -544.04%
2024 -777.000 655.6%
2025 -8.517.000 90.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PetMed Express, Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 552.096
2001 241.888 -128.24%
2002 555.645 56.47%
2003 744.596 25.38%
2004 741.740 -0.39%
2005 171.757 -331.85%
2006 758.176 77.35%
2007 1.025.079 26.04%
2008 502.706 -103.91%
2009 3.692.615 86.39%
2010 1.046.849 -252.74%
2011 677.000 -54.63%
2012 705.000 3.97%
2013 626.000 -12.62%
2014 45.000 -1291.11%
2015 918.000 95.1%
2016 20.130.000 95.44%
2017 10.604.000 -89.83%
2018 703.000 -1408.39%
2019 620.000 -13.39%
2020 2.311.000 73.17%
2021 2.432.000 4.98%
2022 1.752.000 -38.81%
2023 5.260.000 66.69%
2024 4.511.000 -16.6%
2024 984.000 -358.43%
2025 683.000 -44.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PetMed Express, Inc. Equity
Year Equity Growth
2000 1.630.852
2001 757.287 -115.35%
2002 1.582.700 52.15%
2003 5.592.688 71.7%
2004 13.994.509 60.04%
2005 24.217.064 42.21%
2006 37.639.529 35.66%
2007 53.863.573 30.12%
2008 67.033.975 19.65%
2009 74.968.004 10.58%
2010 96.857.213 22.6%
2011 97.005.000 0.15%
2012 81.181.000 -19.49%
2013 64.014.000 -26.82%
2014 70.217.000 8.83%
2015 75.435.000 6.92%
2016 83.195.000 9.33%
2017 93.366.000 10.89%
2018 115.731.000 19.32%
2019 134.680.000 14.07%
2020 130.010.000 -3.59%
2021 141.281.000 7.98%
2022 142.186.000 0.64%
2023 123.795.000 -14.86%
2024 113.671.000 -8.91%
2024 96.731.000 -17.51%
2025 93.531.000 -3.42%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PetMed Express, Inc. Assets
Year Assets Growth
2000 6.326.435
2001 4.504.757 -40.44%
2002 4.654.236 3.21%
2003 9.025.796 48.43%
2004 18.480.808 51.16%
2005 28.119.483 34.28%
2006 42.624.159 34.03%
2007 61.218.487 30.37%
2008 73.454.647 16.66%
2009 81.962.939 10.38%
2010 104.169.858 21.32%
2011 106.287.000 1.99%
2012 91.064.000 -16.72%
2013 73.179.000 -24.44%
2014 78.375.000 6.63%
2015 82.852.000 5.4%
2016 90.279.000 8.23%
2017 112.809.000 19.97%
2018 134.836.000 16.34%
2019 154.427.000 12.69%
2020 155.323.000 0.58%
2021 187.497.000 17.16%
2022 176.319.000 -6.34%
2023 164.117.000 -7.43%
2024 159.271.000 -3.04%
2024 175.093.000 9.04%
2025 152.714.000 -14.65%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PetMed Express, Inc. Liabilities
Year Liabilities Growth
2000 4.695.583
2001 3.747.470 -25.3%
2002 3.071.536 -22.01%
2003 3.433.108 10.53%
2004 4.486.299 23.48%
2005 3.902.419 -14.96%
2006 4.984.630 21.71%
2007 7.354.914 32.23%
2008 6.420.672 -14.55%
2009 6.994.935 8.21%
2010 7.312.645 4.34%
2011 9.282.000 21.22%
2012 9.883.000 6.08%
2013 9.165.000 -7.83%
2014 8.158.000 -12.34%
2015 7.417.000 -9.99%
2016 7.084.000 -4.7%
2017 19.443.000 63.57%
2018 19.105.000 -1.77%
2019 19.747.000 3.25%
2020 25.313.000 21.99%
2021 46.216.000 45.23%
2022 34.133.000 -35.4%
2023 40.322.000 15.35%
2024 45.600.000 11.57%
2024 78.362.000 41.81%
2025 59.183.000 -32.41%

PetMed Express, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
13.2
Net Income per Share
-0.16
Price to Earning Ratio
-24.61x
Price To Sales Ratio
0.31x
POCF Ratio
-17.36
PFCF Ratio
-9.43
Price to Book Ratio
0.88
EV to Sales
0.14
EV Over EBITDA
7.93
EV to Operating CashFlow
-8.05
EV to FreeCashFlow
-4.36
Earnings Yield
-0.04
FreeCashFlow Yield
-0.11
Market Cap
0,08 Bil.
Enterprise Value
0,04 Bil.
Graham Number
4.1
Graham NetNet
0.06

Income Statement Metrics

Net Income per Share
-0.16
Income Quality
1.42
ROE
-0.03
Return On Assets
-0.01
Return On Capital Employed
-0.01
Net Income per EBT
1.97
EBT Per Ebit
0.38
Ebit per Revenue
-0
Effective Tax Rate
-0.97

Margins

Sales, General, & Administrative to Revenue
0.17
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
-0.01
Gross Profit Margin
0.26
Operating Profit Margin
-0
Pretax Profit Margin
-0
Net Profit Margin
-0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-1.92
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.23
Free CashFlow per Share
-0.43
Capex to Operating CashFlow
-0.85
Capex to Revenue
0.01
Capex to Depreciation
0.57
Return on Invested Capital
-0.08
Return on Tangible Assets
-0.03
Days Sales Outstanding
3.05
Days Payables Outstanding
44.37
Days of Inventory on Hand
46.28
Receivables Turnover
119.76
Payables Turnover
8.23
Inventory Turnover
7.89
Capex per Share
0.2

Balance Sheet

Cash per Share
2,24
Book Value per Share
4,56
Tangible Book Value per Share
2.74
Shareholders Equity per Share
4.56
Interest Debt per Share
0.07
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
-9.24
Current Ratio
1.33
Tangible Asset Value
0,06 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
84102000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.24
Average Receivables
0,00 Bil.
Average Payables
0,03 Bil.
Average Inventory
27038000
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PetMed Express, Inc. Dividends
Year Dividends Growth
2009 0
2010 0 0%
2011 1 0%
2012 1 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 100%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%

PetMed Express, Inc. Profile

About PetMed Express, Inc.

PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, and other pet supplies. It sells its products through its Internet website; mobile app; telephone contact center; and direct mail/print, which includes brochures and postcards, as well as television advertising under the 1-800-PetMeds and PetMeds brands. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.

CEO
Ms. Sandra Y. Campos
Employee
287
Address
420 South Congress Avenue
Delray Beach, 33445

PetMed Express, Inc. Executives & BODs

PetMed Express, Inc. Executives & BODs
# Name Age
1 Mr. Doug Krulik
Chief Accounting Officer
70
2 Ms. Christine Chambers
Treasurer & Secretary
70
3 Ms. Robyn DElia
Chief Financial Officer
70
4 Ms. Sandra Y. Campos
President, Chief Executive Officer & Director
70
5 Ms. Caroline Conegliano
Chief Operating Officer
70

PetMed Express, Inc. Competitors